Formoterol fumarate dihydrate

Bezeichnung:Formoterol fumarate dihydrate

CAS-Nr183814-30-4

Englisch Name:Formoterol fumarate dihydrate

CBNumberCB02130563

SummenformelC23H28N2O8

Molgewicht460.48

MOL-Datei183814-30-4.mol

Formoterol fumarate dihydrate physikalisch-chemischer Eigenschaften

Schmelzpunkt	116-120°C
storage temp.	2-8°C
Löslichkeit	DMSO: soluble20mg/mL
Aggregatzustand	solid
Farbe	white to off-white
InChIKey	RATSWNOMCHFQGJ-XODSYJLDSA-N
SMILES	C(/C(=O)O)=C\C(=O)O.[C@@H](C1C=CC(O)=C(NC=O)C=1)(O)CN[C@@H](C)CC1C=CC(OC)=CC=1 \|&1:8,22,r\|
CAS Datenbank	183814-30-4

Sicherheit

RIDADR	UN 2811 6.1 / PGII
WGK Germany	3
HS Code	29242990

Gefahreninformationscode (GHS)

Formoterol fumarate dihydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
Pale Yellow Solid
Verwenden
Formoterol is a selective β2-adrenergic receptor agonist. Formoterol is used as an antiasthmatic.
Verwenden
ForMoterol FuMarate Dihydrate is a selective β2-adrenergic receptor agonist,it is used as an antiasthmatic.
Biologische Aktivität
Potent, selective and long-acting β 2 -adrenoceptor agonist. Displays 330-fold selectivity for β 2 over β 1 receptors (pK d values are 8.12 and 5.58 respectively). Potently relaxes guinea pig trachea (pD 2 = 9.29), and is longer-acting and 100-fold more potent than salbutamol.
Biochem/physiol Actions
β2-Adrenoreceptor agonist.
Arzneimittelwechselwirkung
The efficacy and tolerability of glycopyrronium/formoterol fumarate metered dose inhaler, a fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) delivered by metered dose inhaler using innovative co-suspension delivery technology, was investigated in patients (n = 292) with COPD [12C]. There were no meaningful pharmacokinetic interactions, whether drug–drug or due to formulation, between glycopyrronium and formoterol following treatment with formulated using a new co-suspension delivery technology. The incidence of cardiovascular events of special interest was low (stroke, 0%–0.4%; cardiac ischemia, 0.4%–2.3%; cardiac failure, 1.3%–2.5%; arrhythmia, 1.3%–3.2%), and no important trends in clinical laboratory results, vital signs, or electrocardiograms were observed[1].
Einzelnachweise
[1] Aagaard, Lise . "A worldwide yearly survey of new data in adverse drug reactions." (2014).

Formoterol fumarate dihydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

183814-30-4, Formoterol fumarate dihydrate Verwandte Suche:

Send Inquriy